CDx^® Technology

CDx Diagnostics^™ utilizes patented CDx^® Technology - a combination of a minimally invasive "brush" biopsy with proprietary tissue analysis technologies and specially trained pathologists to increase the detection of the precursors of oral, laryngeal and esophageal cancer. Although these cancers can be prevented when detected at the precursor (i.e., dysplastic) stage, they historically have had some of the lowest survival rates of any cancers due to late detection and the limitations of conventional diagnostic methods.

Today, clinicians use CDx^® patented brush biopsy instruments to non-invasively collect a wide area, disaggregated tissue specimen of the entire thickness of the suspect epithelium. This unique tissue specimen is then subjected to specialized, computer-assisted laboratory analysis. The high sensitivity of the CDx tests is due to the proprietary computer imaging system that is based on an algorithm developed as part of the "Star Wars" missile defense program. This neural network performs sophisticated tests on every cell on the slide, allowing any sign of potential abnormality to be caught at the earliest possible stage. The approximately 200 most "suspicious" cells are then flagged for the pathologists as a starting point for analysis. The pathologists make the diagnosis, and the result is then delivered in the form of a brush biopsy report.

Over 500,000 of these life saving tests have been performed nationally by gastroenterologists, otolaryngologists, oral surgeons, periodontists, and dentists; resulting in the thousands of dysplasias being identified and removed before cancer could start.